InspireMD, Inc. (NSPR)
NASDAQ: NSPR · Real-Time Price · USD
1.150
-0.030 (-2.54%)
At close: May 1, 2026, 4:00 PM EDT
1.080
-0.070 (-6.09%)
Pre-market: May 4, 2026, 7:11 AM EDT
Company Description
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally.
It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Carotid Stent System; and SwitchGuard neuroprotection system to provide flow reversal of cerebral protection in carotid interventions, as well as treating acute stroke with tandem lesions.
The company was founded in 2005 and is headquartered in Miami, Florida.
InspireMD, Inc.
| Country | United States |
| Founded | 2005 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 127 |
| CEO | Marvin Slosman |
Contact Details
Address: 6303 Waterford District Drive, Suite 215 Miami, Florida 33126 United States | |
| Phone | 888 776 6804 |
| Website | inspiremd.com |
Stock Details
| Ticker Symbol | NSPR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001433607 |
| CUSIP Number | 45779A853 |
| ISIN Number | US45779A8466 |
| Employer ID | 26-2123838 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Marvin L. Slosman | President, Chief Executive Officer and Director |
| Michael A. Lawless | Chief Financial Officer, Secretary and Treasurer |
| Shane Thomas Gleason | Chief Commercial Officer |
| Donna DeChant | Vice President of Human Resources and Organizational Development |
| Amir Kohen | Executive Vice President of Finance and Regional Manager |
| Peter J. Ligotti | Executive Vice President and GM of North America |
| Dr. Peter A. Soukas M.D. | Chief Medical Officer |
| Dr. Sol J. Barer Ph.D. | Special Advisor to the Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 1, 2026 | 8-K | Current Report |
| Apr 24, 2026 | SCHEDULE 13D | Filing |
| Apr 22, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 20, 2026 | ARS | Filing |
| Apr 20, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 20, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 10, 2026 | PRE 14A | Other preliminary proxy statements |
| Apr 3, 2026 | 8-K | Current Report |
| Apr 3, 2026 | 424B5 | Filing |
| Mar 18, 2026 | 10-K | Annual Report |